Category

News

NED Biosystems Honors Rebecca Lambert Bent’s Legacy (1947-2026)

By News, Press

It is with profound sadness that we share the passing of Rebecca Lambert Bent, Founder, President, and Executive Chair of NED Biosystems, who died peacefully and surrounded by her family on August 11 following a short illness.

Rebecca worked passionately and, with her characteristic tenacity, sought to advance a systems-based approach to cancer treatment globally. As President and CEO, she led the development of the company’s oral cancer protocol, NED-170, and guided NED-170 through crucial preparation for its clinical trial. Her vision was shaped by decades of entrepreneurial, civic, and public service leadership, and by her commitment to addressing late-stage cancers in a fundamentally different way.

Those within Rebecca’s magnetic orbit knew her as a determined and original thinker whose energy, conviction, and ability to bring people together helped build the foundation on which the company stands today. Her work with respected scientific leaders, including her original mentor Judah Folkman, MD, and more recently DNA sequencer inventor LeRoy Hood, MD, PhD, among others, reflected both her ambition for NED and her belief that meaningful progress in treating complex diseases requires collaboration across disciplines.

On behalf of the entire NED team and Board, we extend our deepest condolences to Rebecca’s family and all who knew and loved her.

We remain committed to honoring Rebecca’s legacy by continuing the work she began with care, discipline, and purpose. NED’s Board has confirmed effective immediately that the Company’s leadership roles are as follows: Geoffrey Ling, MD, PhD, Col (Ret) is Chair of the Board of Directors; José Miguel Trevejo, MD, PhD is serving as Interim CEO; Elinor Mullins is President; and Mary Davis is Treasurer.

As we seek to realize Rebecca’s vision that all cancer patients have access to treatment that provides quality-of-life, lacks toxicity, and allows them to remain productive members of their community, we are more dedicated than ever to advancing NED-170 into its phase 2a clinical trial on a path that honors her hard work.


A longtime resident of Washington, CT, and summer resident of Nantucket, MA, Rebecca was born in Binghamton, NY, daughter of Dr. Abol Hassan and Eleanor Fotouhi.

She attended Williams College and graduated from Simmons College with a bachelor’s degree in political science in 1969. She completed Harvard Business School’s advanced management program in 1982, where she was the sole woman in her class and also ran the Boston Marathon.

She was a longtime congregant and vestry member of St. John’s Church, in Washington, CT, and St. Paul’s Church on Nantucket.

She leaves her husband Ted, her son, Max (Holly) of Richmond, VA, and their two children, and a daughter, Insha Afsar.

Rebecca founded NED Biosystems, a public benefit corporation, to develop her unique systems-approach to cancer treatment which is now preparing for a clinical trial.

Earlier in her political and entrepreneurial career, in 1985 Rebecca acquired five FM radio stations and upgraded each to become Top-100 market properties.

Then, in 1988 she founded Lambert Communications, creating what became the largest multi-channeled, broadcast satellite network serving U.S. hospitals. Subsequently in 2001 she led funds acquisition for Shaker Investments to $1 billion under management.

Prior to these entrepreneurial initiatives, Rebecca began her career managing grass-roots political strategy for statewide campaigns, first in Vermont and then in Wyoming for Senator Malcolm Wallop’s upset victory in 1976, after which she served as chief of staff for both Senator Ted Stevens’ national Republican senatorial committee and for Senator Wallop. Subsequently she was appointed deputy assistant secretary, Department of Energy; and then associate deputy secretary, Department of Commerce, where she initiated the federal government’s first use of a memorandum of understanding related to Brazilian hydro projects.

In the civic sector, Rebecca was president of the Bellevue Hospital Association in New York; an associate trustee of the NYU Medical Center Board; and a member of both the Harvard Women’s Leadership Board and the Women’s Forum of New York.

NED Biosystems Appoints Yanchun “Lily” Li to the Board of Directors

By News

NED Biosystems is thrilled to announce the appointment to its Board of Directors of distinguished entrepreneur, investor, and global philanthropist, Yanchun “Lily” Li. Ms. Li brings an international strategic focus to the Board. Guided by her global vision and humanistic values, Ms. Li has decades of experience building bridges between business, academia, and humanitarian causes – creating meaningful impact. Her expertise will enhance NED’s ability to support cancer patients worldwide.

Ms. Li made history in 2005 for leading the first IPO of a mainland Chinese pharmaceutical company to IPO on the New York Stock Exchange (NYSE) with the company she co-founded, American Oriental Bioengineering [AOBO]. She was recognized as a “discoverer of the stock market” for her cross-border entrepreneurship.

Ms. Li is currently the Founder and Chairperson of Harvard Wealth Strategy & Management which provides strategy for investment between China and the U.S. Her experience advising founders and CEOs on IPOs, financings, mergers and acquisitions, and corporate restructuring is invaluable at this stage of NED’s development. In 2018, at the invitation of Ambassador Nicholas Burns (former U.S. Deputy Secretary of State and then current U.S. Ambassador to China), Ms. Li became an active contributor to Harvard University’s Future of Diplomacy Project, promoting research and dialogue on peace, leadership, and global security.

Previously, Ms. Li was on Harvard Kennedy School’s Dean’s Council, and a member of the Harvard Kennedy School of Government’s Women’s Leadership Board. Ms. Li currently serves as a Trustee of the International Vaccine Institute (IVI), supporting global health initiatives focused on equitable vaccine access and life sciences innovation.

Ms. Li’s appointment to NED’s Board of Directors supports NED’s mission as a Delaware Public Benefit Corporation to impact patients across the globe who currently lack access to care.

 

About NED Biosystems:

 

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company focused on providing systems treatments for patients and their families. NED’s mission is to enable patients to achieve and sustain No Evidence of Disease.  The Company’s novel platform has designed treatments to address large unmet needs for cancer and infectious disease patients. The Company’s goal is to develop treatments that achieve what today’s HIV treatments have: to transform what may be a death sentence diagnosis to No Disease, or reliably managed disease with quality of life.

NED’s novel platform pioneers a data-driven methodology. By simultaneously and redundantly affecting the processes driving disease, well-established by decades of research, treatments are designed to arrest disease progression and normalize disease-related imbalances. Deploying safe, evidenced-based agents lacking customary toxicity and side effects, NED’s treatments are comprehensive unlike today’s narrowly targeted therapies.

NED is a Delaware Public Benefit Company seeking to make its therapies accessible in both developed and developing countries.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact info@nedbiosystems.com.

PHOTO links for media:

https://nedbiosystems.com/wp-content/uploads/2025/11/Li-Lily_website-e1762970718347.jpg

Caption: Lily Li, NED Biosystems’ New Director to the Board.

NED Biosystems Appoints José Trevejo, MD, PhD to the Board of Directors

By News

NED Biosystems strengthened its Board of Directors with the appointment of a highly accomplished physician-scientist and biotechnology executive, José Trevejo, MD, PhD. The appointment of Dr. Trevejo, who has led organizations in the development of high impact medicines spanning multiple therapeutic areas, will bring a key life sciences expertise to the Board. His current work in developing transformative therapies using nature’s chemistry is also well aligned with NED’s own incorporation of natural substances into systems-based approaches that promise to transform how cancer patients are treated globally.

Dr. Trevejo is currently the Chief Medical Officer and Head of Clinical Pipeline Strategy at Enveda Biosciences which is developing new medicines from natural products utilizing AI. Prior to Enveda he was the CMO of Tarsus Pharma where he helped lead the FDA approval and successful launch of a novel category-creating ophthalmology drug. Dr. Trevejo also served as CDO for Rocket Pharmaceuticals and CEO of the non-viral gene therapy company SmartPharm, which was acquired in 2020. Prior to SmartPharm, Dr. Trevejo held increasing roles of responsibility at Ironwood, Genentech and Vertex Pharmaceuticals. Dr. Trevejo received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D./Ph.D. Program and completed his residency and specialty training at Harvard Medical School affiliates BWH and BIDMC.

Dr. Trevejo will support NED’s mission as a Delaware Public Benefit Corporation to reach patients across the globe who currently lack access to care.

 

About NED Biosystems:

 

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company focused on patients and their families. NED’s mission is to enable patients to achieve and sustain No Evidence of Disease.  The Company’s novel platform has designed treatments to address large unmet needs for cancer and infectious disease patients. The intent is to achieve what today’s HIV treatments have: to transform what may be a death sentence diagnosis to No Disease, or reliably managed disease with quality of life.

NED’s novel platform pioneers a data-driven methodology. By simultaneously and redundantly affecting the processes driving disease, well-established by decades of research, treatments are designed to arrest disease progression and normalize disease-related imbalances. Deploying safe, evidenced-based agents lacking customary toxicity and side effects, NED’s treatments are comprehensive unlike today’s narrowly targeted therapies.

NED is a Delaware Public Benefit Company seeking to make its therapies accessible in both developed and developing countries.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact info@nedbiosystems.com.

PHOTO links for media:

https://nedbiosystems.com/wp-content/uploads/2020/07/Trevejo-Jose_square-low-res-e1733927422620.jpg

Caption: José Trevejo, MD, PhD, NED Biosystems’ New Director to the Board.

NED Biosystems Appoints John Thomas, CPA to the Board of Directors

By News

NED Biosystems has added key finance expertise to its Board of Directors through the recent appointment of John Thomas, CPA. Mr. Thomas brings to the board almost 40 years of executive experience in corporate finance. He has guided life sciences companies through the full spectrum of development from the formation of the company and the initial fund-raising efforts to the sale transaction or initial public offering. This wealth of experience will be invaluable to NED as it moves through its upcoming financing round and into clinical development.

 

Since 1986, Mr. Thomas has worked for Mr. Steve Gorlin and served as the Chief Financial Officer for CytRx Corporation, CytRx Biopool, Medicis Pharmaceutical Corp, EntreMed, Inc., ClearPoint Neuro, Inc., DARA BioSciences, MiMedx Group, Inc., DemeRx, Inc., SmartPharm Therapeutics, Inc., and CoRegen, Inc. Mr. Thomas has also served as a Director of NantKwest, Inc., Novelion Therapeutics, Inc., and presently serves as a Director of Dogwood Therapeutics. In addition, Mr. Thomas has also served as CFO of multiple private companies. Prior to working with Mr. Gorlin, Mr. Thomas began his career working at Arthur Andersen & Co. Mr. Thomas also served as a Trustee and Chairman of the Finance Committee of The Walker School, a private Pre-K through 12 grade school. Mr. Thomas is a Certified Public Accountant and graduated from the University of Virginia.

 

Mr. Thomas will support NED’s mission as a Delaware Public Benefit Corporation to reach patients across the globe who currently lack access to care.

 

About NED Biosystems:

 

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company focused on patients and their families. NED’s mission is to enable patients to achieve and sustain No Evidence of Disease.  The Company’s novel platform has designed treatments to address large unmet needs for cancer and infectious disease patients. The intent is to achieve what today’s HIV treatments have: to transform what may be a death sentence diagnosis to No Disease, or reliably managed disease with quality of life.

 

NED’s novel platform pioneers a data-driven methodology. By simultaneously and redundantly affecting the processes driving disease, well-established by decades of research, treatments are designed to arrest disease progression and normalize disease-related imbalances. Deploying safe, evidenced-based agents lacking customary toxicity and side effects, NED’s treatments are comprehensive unlike today’s narrowly targeted therapies.

 

NED is a Delaware Public Benefit Company seeking to make its therapies accessible in both developed and developing countries.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact info@nedbiosystems.com.

PHOTO links for media:

https://nedbiosystems.com/wp-content/uploads/2024/12/Thomas-John-e1733927921157.jpg

Caption: John Thomas, CPA, NED Biosystems’ New Director to the Board.

Institute for Systems Biology and NED Biosystems Will Collaborate to Reverse Cancer Onset

By News, Press
From Inside Precision Medicine

 

The Institute for Systems Biology (ISB) and NED Biosystems (NED) will collaborate on an intriguing clinical trial that aims to use a cocktail of several marketed medications at low doses to reverse cancer’s onset or regrowth. Leroy Hood, MD, PhD, co-founder of ISB and Rebecca Lambert, founder and CEO of NED Biosystems, announced the deal at the end of October.

The Phase 1b/2 clinical trial will use NED-170, which was designed as a systems biology approach. The regimen combines repurposed, marketed drugs, and nutraceuticals that are documented to affect critical cancer disease-driver processes in people. It employs smaller doses in an effort to avoid toxicity and side effects.

“NED is a totally new type of therapy,” says Sui Huang, MD, PhD, an ISB professor. “We are pioneering a systems biology approach to cancer.”

The trial will use multi-dimensional monitoring of the tissue surrounding tumors using a blood test that employs the latest ultra-sensitive, hyper-personalized, proteomics technologies. This approach can measure traces of more than 3,000 distinct proteins at once that reveal many processes in the tumor tissue, thereby offering evidence about which of the individual agents in NED-170 will be useful for a particular patient.

“We use the Olink technology for proteomics, which changes everything,” says Huang, “With our omics expertise and these tools we can provide a truly systems view of what’s happening in patients.”

NED-170 was evaluated pre-clinically for tolerability and efficacy using a murine xenograft model. The company also has a compassionate expanded access program for patients with advanced tumors who either seek alternatives to standard-of-care (SOC) chemotherapy or whose tumors have progressed through available SOC options.

“A systems biology approach is paramount—NED-170 is the multi-pronged treatment required to subvert cancer’s complex system,” says Hood.

The trial is designed to treat patients undergoing standard of care who lack an option for targeted therapy based on tumor genome sequencing. It will cover three indications representing large unmet needs: cholangiocarcinoma, triple negative breast cancer, and ovarian cancer.

NED is initially targeting the 50% to 80% of cancer patients whose tumors do not carry mutations for targeted therapy. Based on observational data, NED believes its systems treatment, when combined with standard of care therapies, may afford patients extended survival and enhanced quality of life.

The data collected from NED’s initial trial and follow-on clinical trials will serve to develop a database for ISB’s large study utilizing proteomics and NED-170 to optimize the systems approach for suppression of cancer progression based on driver processes in subclasses of patients.

High-dimensional profiling of a patient’s blood biochemistry baseline, the team says, can provide information about how the tumor bed is preparing for outgrowth before a the cancer is clinically detectable, which can be a different process in different patients. It can also tell precisely which biological processes a particular tumor relies on most to (re)grow in a given patient. NED believes uncommon quality of life improvements (and cost savings) may be achieved when a cancer patient is treated with evidence-based agents efficacious against key pathways even at low doses.

“By moderating multiple cancer progressing pathways and cancer stem cells at once, NED-170 affords a comprehensive systems approach never before available to cancer patients,” says Lambert. “The comprehensive blood profiling utilized to measure NED-170’s impact on pathways advances a personalized measurement of each patient’s unique cancer signature.”

 

About Inside Precision Medicine
Inside Precision Medicine is the leading source of practical insights for pathologists, clinicians, researchers, and scientists working to translate important findings across the broad range of “omics” technologies to deliver on the promise of molecular and precision medicine for patients.

Institute for Systems Biology and NED Biosystems announce collaboration to show how cancer’s onset may be reversed

By News, Press

NED’s cancer treatment, NED-170, takes a systems approach that combines repurposed, oral agents that are well documented in humans to affect critical cancer disease-driver processes at doses that lack customary toxicity and side effects

SEATTLE – Leroy Hood, MD, PhD, co-founder of Seattle’s Institute for Systems Biology (ISB) and a pioneer in systems biology, and Rebecca Lambert, founder and CEO of NED Biosystems, Inc. (NED), a public benefit corporation that is developing the first oral “systems treatment” for cancer, have entered into a memorandum of understanding to collaborate on a clinical trial to show how cancer’s onset may be reversed.

NED’s cancer treatment, NED-170, takes a systems approach that combines repurposed, oral agents that are well documented in humans to affect critical cancer disease-driver processes at doses that lack customary toxicity and side effects.

“A systems biology approach is paramount – NED-170 is the multi-pronged treatment required to subvert cancer’s complex system,” said Hood, who is inventor of the DNA Sequencer, technology which enabled the Human Genome Project.

The collaborative trial’s objective is to gather intelligence through a multi-dimensional monitoring of the tissue in which a tumor grows. A simple blood test utilizes the latest ultra-sensitive hyper-personalized proteomics technologies to measure the traces of more than 3,000 distinct proteins at once that reveal many processes in the tumor tissue, thereby offering an assessment of the specific efficacy of the individual agents in the multi-pronged approach.

NED-170’s Phase 1b/2 clinical trial is designed to treat patients concomitant to standard of care who lack an option for targeted therapy based on tumor genome sequencing in three indications representing large unmet needs: cholangiocarcinoma, triple negative breast cancer, and ovarian cancer.

NED is initially targeting the 50 percent to 80 percent of cancer patients whose tumors do not carry mutations for targeted therapy. Based on observational data, NED believes its systems treatment, when combined with standard of care therapies, may afford patients extended survival and enhanced quality of life. The data collected from NED’s initial trial and follow-on clinical trials will serve to develop a database for ISB’s large study utilizing proteomics and NED-170 to optimize the systems approach for suppression of cancer progression based on the driver processes in subclasses of patients.

“A truly comprehensive approach to a complex adaptive system like cancer, as the war on global terror has taught us, must be a multi-pronged approach that moderates, without adding stress, the various behaviors that promote cancer and allows the tissue to re-establish the balance of a normal cell community,” said Sui Huang, MD, PhD, and ISB professor, cancer cell dynamics expert, and NED Biosystems Systems Advocate.

The envisioned high-dimensional profiling of a patient’s blood biochemistry baseline can inform doctors about how the tumor bed is preparing a tiny tumor for outgrowth before a tumor is clinically detectable, which can be different in different patients. It can also tell us precisely which biological processes a particular tumor relies on most to (re)grow in a given patient. Uncommon quality of life improvements (and cost savings) may be achieved when a cancer patient is treated with evidence-based agents efficacious against key pathways at doses that lack toxicity and side effects.

“By moderating multiple cancer progressing pathways and cancer stem cells at once, NED-170 affords a comprehensive systems approach never before available to cancer patients,” said Lambert. “The comprehensive blood profiling utilized to measure NED-170’s impact on pathways advances a personalized measurement of each patient’s unique cancer signature.”

 

About ISB

Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, COVID-19, the human microbiome, as well as many infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit health care systems in the United States. Follow us online at isbscience.org, and on YouTube, Facebook, Instagram, LinkedIn and Twitter.

About NED Biosystems

Based in Cambridge, Mass., NED Biosystems is a clinical-stage biotech company founded by Rebecca Lambert to develop safe, efficacious, and comprehensive “systems” treatments for complex disease, beginning with the development of the patented NED-170 for treatment of cancer. Ease of oral dosing, favorable storage conditions and cost-effectiveness of the treatment supports the company’s mission to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations but also in the developing world. Visit NEDbiosystems.com.

NED Biosystems Congratulates Board Director Carolina Alarco on Receiving Impact on Life Sciences Diversity, Equity, & Inclusion Award

By News

NED congratulates our Board Director Carolina Alarco on receiving LabCentral Ignite’s inaugural Ted W. Love Award for Individual Impact on Life Sciences Diversity, Equity, & Inclusion at the first annual bioDiversity Summit Awards Dinner on September 28, 2022.

 

 

Carolina is the founder and principal of BioStrategy Advisors, LLC, a strategic business consulting firm for small and medium-sized biotech and medtech companies in the Massachusetts area. Born in Lima, Peru and a resident of the Boston area for 27 years, her life’s focus is on bringing healthcare innovations to patients around the world and helping Latinx professionals succeed in the life sciences industry – both here in the U.S. and in her home country.

To that end, she serves on the Mass General Board of Trustees (MGPO), the Greater Boston Chamber of Commerce Women’s Advisory Board, the Massachusetts STEM Advisory Council and the Latinx Council at Boston Children’s Hospital. She is also the co-founder of Latinos In Bio, a group dedicated to creating opportunities for success and amplifying the social capital of Latinx professionals in the biotech, pharmaceutical, medical technology, and other fields within life sciences.

NED Biosystems Appoints Two New Board Members: Carolina Alarco and Louise Forlenza, CPA

By News

NED Biosystems welcomes two highly accomplished business development professionals Carolina Alarco and Louise Forlenza, CPA to its Board of Directors. Ms. Alarco and Ms. Forlenza bring over 60 years of combined experience building companies into successful global enterprises. The two will add valuable expertise to the Board.

Ms. Alarco has extensive experience as an executivein biotechnology and pharmaceutical companies at all stages of development. She successfully established international markets for multiple biotech companies including Genzyme, Aegerion Pharmaceuticals, and Novelion Therapeutics. At Genzyme, Ms. Alarco oversaw market development across the international regions and directed the global marketing efforts for numerous orphan drugs as VP until acquisition by Sanofi. As President of Aegerion Pharmaceuticals, she launched 2 orphan drugs and built the company’s international footprint from scratch, culminating in a merger with Novelion Therapeutics in 2017 where she continued on as President of Global Marketing and International Markets. Ms. Alarco’s keen understanding of international markets, fluency in multiple languages, and network of global connections will help NED develop its iconic brand globally. In addition to serving on NED’s Board, She serves on the Board of two private biotech companies, Syte.bio, Inc. and Dione Antibiotics, Inc. Ms. Alarco is Founder and Principal of Bio Strategy Advisors LLC, Strategic Consultant for Interlink Markets, and Founding Venture Partner of ACCELHub Venture Partners. She also  serves on the Mass General Hospital Board of Trustees (MGPO), the Latino Council at Boston Children’s Hospital, the State of Massachusetts STEM Advisory Council and the Board of Latinos in Bio, of which she is co-Founder and past-Chair. She holds a BS in Business Administration from the University of Lima and a Graduate Degree in Business and Management from Harvard University.

Ms. Forlenza, a NY State Licensed CPA, brings over 35 years of experience in corporate finance to the Board. She has a proven track record leading privately and publicly held companies from inception to growth and profitability. Since founding LC Forlenza Advisory Services in 1987, she has advised over 250 long-tenured clients across the globe on a wide range of financial matters including tax and audit strategy, forensic accounting, mergers, and reporting. Throughout the 1980s and early 1990s, Ms. Forlenza led audit and tax relationships with international audit firms on behalf of global brokerage firms Bierbaum-Martin Inc and International Exchange Partners. She led operations for these firms in London, Dusseldorf, and New York. Ms. Forlenza has held numerous board positions advising companies on audit and tax-related matters and currently serves as Chair of the Audit Committee for the Board of Innodata Inc. She holds a Certificate in Forensic Accounting from NYU and BBA in Accounting from Iona College where she was the first and only female accounting major in her graduating class, and she has completed Executive Training Programs at Harvard Business School and The Wharton School.

Together, Ms. Alarco and Ms. Forlenza will support NED’s mission as a Delaware Public Benefit Corporation to reach patients across the globe who currently lack access to care.

 

About NED Biosystems:

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company focused on patients and their families.  NED’s mission is to enable patients to achieve and sustain No Evidence of Disease.  The Company’s novel platform has designed treatments to address large unmet needs for cancer and infectious disease patients. The intent is to achieve what today’s HIV treatments have: to transform what may be a death sentence diagnosis to No Disease, or reliably managed disease with quality of life.

NED’s novel platform pioneers a data-driven methodology. By simultaneously and redundantly affecting the processes driving disease, well-established by decades of research, treatments are designed to arrest disease progression and normalize disease-related imbalances. Deploying safe, evidenced-based agents lacking customary toxicity and side effects, NED’s treatments are comprehensive unlike today’s narrowly targeted therapies.

NED is a Delaware Public Benefit Company seeking to make its therapies accessible in both developed and developing countries.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact info@nedbiosystems.com.

PHOTO links for media:

https://nedbiosystems.com/wp-content/uploads/2022/02/Alarco-Carolina-2-e1645565615667.png

Caption: Carolina Alarco, NED Biosystems’ New Director to the Board.

https://nedbiosystems.com/wp-content/uploads/2022/03/Forlenza-Louise_2022-02-cropped-e1646702904607.png

Caption: Louise Forlenza, CPA, NED Biosystems’ New Director to the Board.

Leading Experts in Cancer Research Nabeel El-Bardeesy and Razelle Kurzrock Join NED Biosystems’ Scientific Advisory Board

By News

CAMBRIDGE, Mass., Sept. 2, 2020 (SEND2PRESS NEWSWIRE) — NED Biosystems, an innovative clinical-stage biotech company developing oral therapies for cancer and novel coronavirus, is pleased to announce that Nabeel El-Bardeesy, PhD and Razelle Kurzrock, MD have joined the Company’s Scientific Advisory Board. Both Dr. El-Bardeesy and Dr. Kurzrock bring a wealth of expertise as scientific and clinical leaders in cancer research and treatments.

Dr. El-Bardeesy is Associate Professor of Medicine at the Harvard Medical School and a leading authority on the causes of cancer. Dr. El-Bardeesy also serves as the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board Co-Chair. Dr. El-Bardeesy additionally is Assistant Professor at Massachusetts General Hospital Cancer Center and is an instructor at the Dana-Farber Cancer Institute. Dr. El-Bardeesy is widely published on the molecular and cellular mechanisms that drive certain types of cancer.

Dr. Kurzrock is Professor of Medicine and Associate Director for Clinical Sciences at the University of San Diego Moore Cancer Center. She leads the Center’s clinical trial programs and heads its recently established Center for Personalized Cancer Therapy. Dr. Kurzrock’s distinguished track record includes leading one of the largest phase one clinical trial programs at the University of Texas MD Anderson Cancer Center, where she spearheaded an innovative approach that utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized the possibility for response.

“The addition of Dr. El-Bardeesy and Dr. Kurzrock to the Scientific Advisory Board further strengthens the resolve of NED’s mission to innovate safe, effective and transformative treatments for cancer and other life-threatening diseases such as Covid-19,” stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems’ Board. “As we advance NED-170 clinical trials for cholangiocarcinoma, ovarian and triple negative breast cancer to establish the product’s safety and efficacy, we will rely heavily on the Scientific Advisory Board’s expert guidance and direction. They will also play an instrumental role in our efforts to launch clinical trials for NED-260, a potential treatment and prophylaxis for COVID-19.*”

NED-170 is a patented investigational cancer therapy that the Company believes is the first to address and affect four key processes that advance all late-stage cancers (Stages II-IV). The same four processes that drive advanced cancers are integral to the pathology of Covid-19.

“The implementation of comprehensive clinical trials is a vitally important step in determining the safety and effectiveness of the treatments for life threatening illnesses that we are innovating at NED Biosystems,” stated Geoffrey Ling, COL(ret) MD, PhD, Office of the CEO, and member of the Scientific Advisory Board and Board of Directors, NED Biosystems and member of the U.S. Government’s Covid-19 Task Force. “The deep expertise of our Scientific Advisory Board provides us with the confidence that we are following the proper methods and techniques to generate a valid set of trial results.”

“Dr. Kurzrock and Dr. El-Bardeesy will provide invaluable guidance on the clinical design and execution for our upcoming NED-170 trials, as well as input into the analysis of the results,” stated Brian Leyland-Jones, BS, MBBS, PhD, FRACP, FRACPC, NED Biosystems Chair of the Scientific Advisory Board. “We are excited to welcome them to the Scientific Advisory Board and look forward to their support of our clinical trial initiatives.”

About NED Biosystems™

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments unlike most available today. Beginning with a focus on patients and their families, NED seeks to dramatically improve patients’ outcomes with therapies that lack the toxicity and side effects of today’s treatments, allowing patients to retain a high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations but also in economically challenged global regions.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact Creative Director, Brett Macias at bmacias@nedbiosystems.com.

*NED-170 and NED-260 are pending approval by the FDA post clinical trials.